OUTCOMES OF PRIMARY TRABECULECTOMY WITH THE USE OF ADJUNCTIVE MITOMYCIN

Citation
Iu. Scott et al., OUTCOMES OF PRIMARY TRABECULECTOMY WITH THE USE OF ADJUNCTIVE MITOMYCIN, Archives of ophthalmology, 116(3), 1998, pp. 286-291
Citations number
42
Categorie Soggetti
Ophthalmology
Journal title
ISSN journal
00039950
Volume
116
Issue
3
Year of publication
1998
Pages
286 - 291
Database
ISI
SICI code
0003-9950(1998)116:3<286:OOPTWT>2.0.ZU;2-B
Abstract
Objective: To investigate the efficacy and safety of adjunctive mitomy cin when used during a primary trabeculectomy wi;hin a series of 89 co nsecutive patients at 1 and 2 years postoperatively. Design: A cohort study of all patients who underwent primary trabeculectomy, performed by one of us (P.F.P.), between April 1, 1991, and December 31, 1994. P atients received topical mitomycin in conjunction with a corneal safet y valve incision. A trabeculectomy was considered ''successfull'' if i t resulted in an intraocular pressure (IOP) of 21 mm Hg or lower and a 30% or greater reduction in the IOP at and after 1 year of follow-up, with or without medications and without a reoperation for an elevated IOP. Survival analysis was used to calculate success rates. Results: The 1- and 2-year success rates were 85.4% and 77.9%, respectively. Th e mean IOP was reduced from 26.3 to 11.3 mm Hg at 1 year (n = 68) and to 11.9 mm Hg at 2 years (n = 56), with 60 (88.2%) of 68 patients off medication at 1 year and 47 (83.9%) of 56 patients off medication at 2 years. Trabeculectomy success rates were significantly lower in black compared with nonblack patients (76.2% vs 87.5% at 1 year, P = .03), Trabeculectomy failure occurred throughout the follow-up period. Endop hthalmitis occurred in 2 (2.2%) of the patients, and hypotonia requiri ng revision occurred in 4 (4.5%) of the patients. Conclusions: Primary trabeculectomy with the use of intraoperative mitomycin lowered the I OP by 30% or more in 78% (at 2 years) to 86% (at 1 year) of the cases and is associated with a marked reduction in the percentage of patient s who require glaucoma medication. Success rates must be evaluated in light of such risks as endophthalmitis and hypotony.